Next generation of biologics for the treatment of Crohn’s disease: an evidence-based review on ustekinumab

References

• GomollónFDignassAAnneseV3rd European evidence-based consensus on the diagnosis and management of Crohn’s Disease 2016: Part 1: diagnosis and medical managementJ Crohns Colitis201711132527660341
   PubMed Web of Science ®Google Scholar
• FDA Product InformationApproval of ustekinumab for Crohn’s disease2016 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/761044Orig1s000ltr.pdf
   Google Scholar
• EMA Product informationApproval of ustekinumab for Crohn’s disease2016 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Product_Information/human/000958/WC500058513.pdf
   Google Scholar
• NeurathMFCytokines in inflammatory bowel diseaseNat Rev Immu-nol2014145329342
   PubMed Web of Science ®Google Scholar
• OppmannBLesleyRBlomBNovel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12Immunity200013571572511114383
   PubMed Web of Science ®Google Scholar
• CuaDJSherlockJChenYInterleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brainNature2003421692474474812610626
   PubMed Web of Science ®Google Scholar
• TengMWBowmanEPMcElweeJJIL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseasesNat Med201521771972926121196
   PubMed Web of Science ®Google Scholar
• NeurathMFFussIKelsallBLStüberEStroberWAntibodies to interleukin 12 abrogate established experimental colitis in miceJ Exp Med19951825128112907595199
   PubMed Web of Science ®Google Scholar
• UhligHHMcKenzieBSHueSDifferential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathologyImmunity200625230931816919486
   PubMed Web of Science ®Google Scholar
• TozawaKHanaiHSugimotoKEvidence for the critical role of interleukin-12 but not interferon-gamma in the pathogenesis of experimental colitis in miceJ Gastroenterol Hepatol200318557858712702051
   PubMed Web of Science ®Google Scholar
• YenDCheungJScheerensHIL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6J Clin Invest200611651310131616670770
   PubMed Web of Science ®Google Scholar
• IzcueAHueSBuonocoreSInterleukin-23 restrains regulatory T cell activity to drive T cell-dependent colitisImmunity200828455957018400195
   PubMed Web of Science ®Google Scholar
• AhernPPSchieringCBuonocoreSInterleukin-23 drives intestinal inflammation through direct activity on T CellsImmunity201033227928820732640
   PubMed Web of Science ®Google Scholar
• BensonJMSachsCWTreacyGTherapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumabNat Biotechnol201129761562421747388
   PubMed Web of Science ®Google Scholar
• LeonardiCLKimballABPappKAPHOENIX1 study investigatorsEfficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)Lancet200837196251665167418486739
   PubMed Web of Science ®Google Scholar
• PappKALangleyRGLebwohlMPHOENIX 2 study investigatorsEfficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)Lancet200837196251675168418486740
   PubMed Web of Science ®Google Scholar
• GriffithsCEStroberBEvan de KerkhofPACCEPT Study GroupComparison of ustekinumab and etanercept for moderate-to-severe psoriasisN Engl J Med2010362211812820071701
   PubMed Web of Science ®Google Scholar
• TsaiTFHoJCSongMPEARL InvestigatorsEfficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL)J Dermatol Sci201163315416321741220
   PubMed Web of Science ®Google Scholar
• IgarashiAKatoTKatoMSongMNakagawaHJapanese Ustekinumab Study GroupEfficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: Long-term results from a phase 2/3 clinical trialJ Dermatol201239324225221955098
   PubMed Web of Science ®Google Scholar
• GottliebAMenterAMendelsohnAUstekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trialLancet2009373966463364019217154
   PubMed Web of Science ®Google Scholar
• McInnesIBKavanaughAGottliebABEfficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trialLancet2013382989478078923769296
   PubMed Web of Science ®Google Scholar
• RitchlinCRahmanPKavanaughAPSUMMIT 2 Study GroupEfficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trialAnn Rheum Dis201473699099924482301
   PubMed Web of Science ®Google Scholar
• KavanaughARitchlinCRahmanPPSUMMIT-1 and 2 Study GroupsUstekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-cAnn Rheum Dis20147361000100624553909
   PubMed Web of Science ®Google Scholar
• SandbornWJGasinkCGaoLLCERTIFI Study GroupUstekinumab induction and maintenance therapy in refractory Crohn’s diseaseN Engl J Med2012367161519152823075178
   PubMed Web of Science ®Google Scholar
• FeaganBGSandbornWJGasinkCUNITI–IM-UNITI Study GroupUstekinumab as Induction and Maintenance Therapy for Crohn’s DiseaseN Engl J Med2016375201946196027959607
   PubMed Web of Science ®Google Scholar
• MacDonaldJKNguyenTMKhannaRTimmerAAnti-IL-12/23 p40 antibodies for induction of remission in Crohn’s diseaseCochrane Database Syst Rev201611CD00757227885650
   PubMedGoogle Scholar
• KopylovUAfifWCohenASubcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn’s disease-The McGill experienceJ Crohn’s Colitis20148111516152224996483
   PubMedGoogle Scholar
• WilsPBouhnikYMichettiPGroupe d’Etude Thérapeutique des Affections Inflammatoires du Tube DigestifSubcutaneous ustekinumab provides clinical benefit for two-thirds of patients with Crohn’s disease refractory to anti-tumor necrosis factor agentsClin Gastroenterol Hepatol2016142242250e1e226432476
   PubMed Web of Science ®Google Scholar
• HarrisKAHorstSGadaniAPatients with refractory Crohn’s disease successfully treated with UstekinumabInflamm Bowel Dis201622239740126752468
   PubMed Web of Science ®Google Scholar
• ToedterGPBlankMLangYChenDSandbornWJde VilliersWJRelationship of C-reactive protein with clinical response after therapy with ustekinumab in Crohn’s diseaseAm J Gastroenterol2009104112768277319672253
   PubMed Web of Science ®Google Scholar
• MaCFedorakRNKaplanGGClinical, endoscopic and radio-graphic outcomes with ustekinumab in medically-refractory Crohn’s disease: real world experience from a multicentre cohortAliment Pharmacol Ther20174591232124328252210
   PubMed Web of Science ®Google Scholar
• Sansó SuredaARocamora DuránVSapiña CamaróARoyo EscosaVBosque LópezMJUstekinumab in a patient with Crohn’s disease and anti-TNFα induced psoriasisGastroenterol Hepatol201134854655021665330
   PubMed Web of Science ®Google Scholar
• AndrisaniGMarzoMCellenoLDevelopment of psoriasis scalp with alopecia during treatment of Crohn’s disease with infliximab and rapid response to both diseases to ustekinumabEur Rev Med Pharmacol Sci201317202831283624174369
   PubMed Web of Science ®Google Scholar
• TillackCEhmannLMFriedrichMAnti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-gamma-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatmentGut201463456757723468464
   PubMed Web of Science ®Google Scholar
• SuhHYAhnJYParkMYYounJIExacerbation of infliximab-induced paradoxical psoriasis after ustekinumab therapyJ Dermatol Epub2017311
   Web of Science ®Google Scholar
• SegalBMConstantinescuCSRaychaudhuriAKimLFidelus-GortRKasperLHUstekinumab MS InvestigatorsRepeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging studyLancet Neurol20087979680418703004
   PubMed Web of Science ®Google Scholar
• LongbrakeEERackeMKWhy did IL-12/IL-23 antibody therapy fail in multiple sclerosis?Expert Rev Neurother20099331932119271940
   PubMed Web of Science ®Google Scholar
• GuenovaETeskeAFehrenbacherBInterleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumabArch Dermatol2011147101203120521680759
   PubMedGoogle Scholar
• ChuDHVan VoorheesASRosenbachMTreatment of refractory tumor necrosis factor inhibitor-induced palmoplantar pustulosis: a report of 2 casesArch Dermatol2011147101228123022006150
   PubMedGoogle Scholar
• GoldminzAMBottoNCGottliebABSeverely recalcitrant pyoderma gangrenosum successfully treated with ustekinumabJ Am Acad Dermatol2012675e237e23823062936
   PubMed Web of Science ®Google Scholar
• GrebJEGottliebABGoldminzAMHigh-dose ustekinumab for the treatment of severe, recalcitrant pyoderma gangrenosumDermatol Ther201629648248327502191
   PubMed Web of Science ®Google Scholar
• FahmyMRamamoorthySHataTSandbornWJUstekinumab for peristomal pyoderma gangrenosumAm J Gastroenterol2012107579479522552250
   PubMed Web of Science ®Google Scholar
• LebwohlMLeonardiCGriffithsCELong-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled phase 2 and 3 clinical trialsJ Am Acad Dermatol201266573174121930328
   PubMed Web of Science ®Google Scholar
• GordonKBPappKALangleyRGLong-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trialsJ Am Acad Dermatol201266574275121978572
   PubMed Web of Science ®Google Scholar
• KimballABPappKAWasfiYPHOENIX 1 InvestigatorsLong-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 studyJ Eur Acad Dermatology Venereol2013271215351545
   PubMed Web of Science ®Google Scholar
• LangleyRGLebwohlMKruegerGGPHOENIX 2 InvestigatorsLong-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-upBr J Dermatol201517251371138325307931
   PubMed Web of Science ®Google Scholar
• PappKGottliebABNaldiLSafety surveillance for ustekinumab and other psoriasis treatments fthe psoriasis longitudinal assessment and registry (PSOLAR)J Drugs Dermatol201514770671426151787
   PubMed Web of Science ®Google Scholar
• KalbREFiorentinoDFLebwohlMGRisk of serious infection with biologic and systemic treatment of psoriasisJAMA Dermatol2015151996196925970800
   PubMed Web of Science ®Google Scholar
• Gómez-GarcíaFEpsteinDIsla-TejeraBLorenteAVélez García-NietoARuanoJShort-term efficacy and safety of new biologic agents targeting IL -23/Th17 pathway for moderate to severe plaque psoriasis: a systematic review and network meta -analysisBr J Dermatol2017176359460327292159
   PubMed Web of Science ®Google Scholar
• MockoPKawalecPPilcASafety profile of biologic drugs in the therapy of Crohn disease: A systematic review and network meta-analysisPharmacol Rep20166861237124327686963
   PubMed Web of Science ®Google Scholar
• HanauerSBFeaganBGLichtensteinGRACCENT I Study GroupMaintenance infliximab for Crohn’s disease: the ACCENT I randomised trialLancet200235993171541154912047962
   PubMed Web of Science ®Google Scholar
• SandsBEAndersonFHBernsteinCNInfliximab maintenance therapy for fistulizing Crohn’s diseaseN Engl J Med2004350987688514985485
   PubMed Web of Science ®Google Scholar
• RegueiroMSchrautWBaidooLInfliximab prevents Crohn’s disease recurrence after ileal resectionGastroenterology2009136244145019109962
   PubMed Web of Science ®Google Scholar
• WatanabeMHibiTLomaxKGStudy InvestigatorsAdalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn’s diseaseJ Crohn’s Colitis20126216017322325170
   PubMedGoogle Scholar
• ColombelJFSandbornWJRutgeertsPAdalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trialGastroenterology20071321526517241859
   PubMed Web of Science ®Google Scholar
• SandbornWJHanauerSBRutgeertsPAdalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trialGut20075691232123917299059
   PubMed Web of Science ®Google Scholar
• SandbornWJFeaganBGRutgeertsPGEMINI 2 Study GroupVedolizumab as induction and maintenance therapy for Crohn’s diseaseN Engl J Med2013369871172123964933
   PubMed Web of Science ®Google Scholar
• SandsBEFeaganBGRutgeertsPEffects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment had failedGastroenterology20141473618627.e324859203
   PubMed Web of Science ®Google Scholar
• SandbornWJSchreiberSFeaganBGCertolizumab pegol for active Crohn’s disease: a placebo-controlled, randomized trialClin Gastroenterol Hepatol20119867067821642014
   PubMed Web of Science ®Google Scholar
• BadatYMeissnerWGLaharieDDemyelination in a patient receiving ustekinumab for refractory Crohn’s diseaseJ Crohns Colitis2014891138113924572561
   PubMed Web of Science ®Google Scholar
• RungapiromnanWYiuZZNWarrenRBGriffithsCEMAshcroftDMImpact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomised controlled trialsBr J Dermatol2017176489090127518205
   PubMed Web of Science ®Google Scholar
• BattatRKopylovUBessissowTAssociation between ustekinumab trough concentrations and clinical, biomarker, and endoscopic outcomes in patients with Crohn’s diseaseClin Gastroenterol Hepatol201715914271434.e228365485
   PubMed Web of Science ®Google Scholar
• BrownSMAljefriKAWaasRHamptonPJSystemic medications used in treatment of common dermatological conditions: safety profile with respect to pregnancy, breast feeding and content in seminal fluidJ Dermatolog Treat Epub2017116
   Web of Science ®Google Scholar
• Götestam SkorpenCHoeltzenbeinMTincaniAThe EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactationAnn Rheum Dis201675579581026888948
   PubMed Web of Science ®Google Scholar
• Galli-NovakEMookSCBüningJSuccessful pregnancy outcome under prolonged ustekinumab treatment in a patient with Crohn’s disease and paradoxical psoriasisJ Eur Acad Dermatol Venereol20163012e191e19226559393
   PubMed Web of Science ®Google Scholar
• CortesXBorrás-BlascoJAntequeraBUstekinumab therapy for Crohn’s disease during pregnancy: a case report and review of the literatureJ Clin Pharm Ther201742223423628004853
   PubMed Web of Science ®Google Scholar
• BishopCSimonHSuskindDLeeDWahbehGUstekinumab in pediatric Crohn disease patientsJ Pediatr Gastroenterol Nutr201663334835126854655
   PubMed Web of Science ®Google Scholar
• RinawiFRosenbachYAssaAShamirRUstekinumab for resistant pediatric Crohn’s diseaseJ Pediatr Gastroenterol Nutr2016624e34e3525023579
   PubMed Web of Science ®Google Scholar
• CameronFLGarrickVRussellRKUstekinumab in treatment of refractory paediatric Crohn diseaseJ Pediatr Gastroenterol Nutr2016623e30
   PubMed Web of Science ®Google Scholar
• HayashiMUmezawaYFukuchiOItoTSaekiHNakagawaHEfficacy and safety of ustekinumab treatment in elderly patients with psoriasisJ Dermatol2014411197498025346301
   PubMed Web of Science ®Google Scholar
• GarberCPlotnikovaNAuSCSorensenEPGottliebABiologic and conventional systemic therapies show similar safety and efficacy in elderly and adult patients with moderate to severe psoriasisJ Drugs Dermatol201514884685226267729
   PubMed Web of Science ®Google Scholar
• SinghSKroe-BarrettRRCanadaKASelective targeting of the IL23 pathway: Generation and characterization of a novel highaffinity humanized anti-IL23A antibodyMAbs20157477879125905918
   PubMed Web of Science ®Google Scholar
• PappKABlauveltABukhaloMRisankizumab versus ustekinumab for moderate-to-severe plaque psoriasisN Engl J Med2017376161551156028423301
   PubMed Web of Science ®Google Scholar
• FeaganBGSandbornWJD’HaensGInduction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn’s disease: a randomised, double-blind, placebo-controlled phase 2 studyLancet2017389100801699170928411872
   PubMed Web of Science ®Google Scholar